The $1 billion agreement will add commercial capacity at Thermo Fisher Scientific’s Greenville, North Carolina site to support pneumococcal conjugate vaccines.
The new construction follows a recently launched active pharmaceutical ingredient facility project in Illinois as part of AbbVie’s $10 billion U.S. investment.
The Stirling site upgrade will support commercial sterile production starting in late 2025 with batch sizes of up to 15,000 vials, according to the CDMO.
The Zhunan facility upgrade will add high-potency, advanced delivery liquid-filled capsule capabilities for complex pharmaceutical ingredients by early 2026.
The project will increase drug production capacity and integrate advanced technologies across operations to strengthen Amgen’s U.S. supply chain, according to the company.
The France-based company’s new Lufkin, Texas site will reportedly boost lipid-based excipient production while reinforcing supply chains across North America.
The South Korea-based manufacturer has outfitted its facility with Thermo Fisher Scientific technologies to scale AAV vector production to commercial levels.
The South Korea–based biosimilars manufacturer said the acquisition secures U.S. manufacturing capacity as part of its long-term tariff response strategy.
The Minnesota-based regenerative medicine company will use Lonza’s Houston site to produce its platelet-derived exosome drug substance for late-stage trials.
The move expands the CDMO’s long-standing Florida presence, which includes a 500,000-square-foot St. Petersburg softgel development and manufacturing facility.
The $100,000 in-kind donation will enhance hands-on training at North Carolina State University’s BTEC facility in Raleigh, near Fujifilm’s expanding Holly Springs site.
The Seattle-headquartered CDMO will close its large-scale mammalian production facilities in Boulder and Longmont by year-end as part of a restructuring plan.
The latest installation at the Morpeth, England facility is designed to support rapid changeovers that enhance the site’s oral solid development and production capabilities.